<DOC>
	<DOCNO>NCT02517918</DOCNO>
	<brief_summary>This prospective open-labeled phase I trial base dose escalate study design assess two dose level sirolimus prescribe combination metronomic cyclophosphamide ( CP ) , methotrexate ( MT ) zoledronic acid ( ZA ) follow expansion cohort Maximum Tolerated Dose ( MTD ) establish .</brief_summary>
	<brief_title>Metronomic Chemotherapy Patients With Advanced Solid Tumor With Bone Metastasis Advanced Pretreated Osteosarcoma</brief_title>
	<detailed_description>The dose escalation part trial concern adult advance solid tumor bone metastasis young adult patient unresectable locally advanced metastatic osteosarcoma . The Expansion cohort conduct young adult patient unresectable locally advanced metastatic osteosarcoma .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>1 . Histology : Advanced solid tumor radiologically proven bone metastasis , ( dose escalation part ) Patients osteogenic osteosarcoma ( dose escalation part expansion cohort ) histologically confirm central review 2 . Metastatic unresectable locally advanced disease , eligible alternative local treatment ( radiotherapy instance ) 3 . Age &gt; 18 year patient solid tumor ≥ 13 year patient osteosarcoma 4 . ECOG , performance status ≤ 1 5 . Life expectancy &gt; 3 month 6 . Measurable disease accord RECIST v1.1 . At least one site disease must unidimensionally ≥ 10 mm 7 . Patients must histologically confirm diagnosis locally advance and/or metastatic solid tumor , amenable standard treatment , include patient osteosarcoma conventional agent anthracyclines , platinum salt , ifosfamide and/or methotrexate 8 . At least three week since last chemotherapy , immunotherapy pharmacological treatment and/or radiotherapy 9 . Adequate haematological , renal , metabolic hepatic function : Haemoglobin ≥ 10 g/dl ( patient may receive prior red blood cell transfusion , clinically indicate ) ; leucocytes ≥ 3 x 10^9/l , absolute neutrophil count ≥ 1.5 x 10^9/l , platelet count ≥ 120 x 10^9/l . Alanine aminotransferase aspartate aminotransferase ≤ 2.5 x upper limit normality ( ULN ) Total bilirubin ≤ 1.5 x ULN Calculated creatinine clearance &gt; 40 ml/min/1.73 m² ( accord MDRD formula ) Creatine phosphokinase ≤ 2.5 x ULN Albumin &gt; 25 g/l 10 . No prior concurrent malignant disease diagnose treat last 2 year except adequately treat situ carcinoma cervix , basal squamous skin cell carcinoma , situ transitional bladder cell carcinoma , 11 . Recovery grade ≤ 1 adverse event derive previous treatment ( exclude alopecia grade nonpainful peripheral neuropathy grade ≤ 2 ) accord NCICTCAE , version 4 12 . Patients French social security compliance French law relate biomedical research 13 . Voluntarily sign date write informed consent prior study specific procedure 14 . Women childbearing potential must negative serum pregnancy test study entry . Both woman men must agree use medically acceptable method contraception throughout treatment period six month discontinuation treatment 1 . Previous treatment sirolimus 2 . Concomitant diseases/conditions : Clinically significant and/or rapidly accumulate ascites , pericardial and/or pleural effusion Unstable cardiac disease , pulse oximetry saturation &lt; 90 % rest Clinically significant immunodeficiency , HIV active Hepatitis B C History autoimmune disease , transplantation 3 . Central nervous system malignancy 4 . Men woman childbearing potential use effective method contraception ; woman pregnant breast feed 5 . Patients receive substance inhibitor inducer CYP450 3A4 6 . Ongoing recent ( &lt; 6 week ) dental problem , include severe tooth jaw infection ( mandible maxilla ) , dental trauma , dental stomatological surgery ( implant ) . Current dental care allow 7 . History maxillary osteonecrosis delay heal dental surgery 8 . Participation study involve medical therapeutic intervention last 30 day 9 . Previous enrolment present study 10 . Patient unable follow comply study procedure geographical , familial , social psychological reason 11 . Known hypersensitivity involve study drug formulation component 12 . Patients receive live vaccine within 30 day prior first dose study therapy participate study</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Advanced solid tumor</keyword>
	<keyword>Bone metastasis advance pretreated osteosarcoma</keyword>
	<keyword>Phase I trial</keyword>
	<keyword>Dose escalation expansion cohort</keyword>
	<keyword>Biomarkers study</keyword>
</DOC>